17,261 trials
Atopic Asthma
Primary: Baseline Percentage of Eosinophils Recovered in the BAL Prior to Segmental Allergen Challenge — 42; 19 percentage of cells
Untreated Childhood Brain Stem Glioma
Primary: One Year Event-free Survival (EFS) — 20 percent probability
Breast Cancer · Cancer Survivor · Hot Flashes
Primary: Percent Difference in Hot Flash Activity (Score) Between Baseline and End of Treatment (Week 5) — -50.4 percentage of difference
Glioblastoma · Gliosarcoma
Primary: 6-month Progression-free Survival (PFS) — 25; 28.6 percentage of participants
Prostate Cancer
Primary: Pathologic Complete Response Was Assessed by Rigorous Pathological Examination by One of Two Pathologists — 0 participants
Lung Cancer
Primary: Progression Free Survival(PFS) — 5.6 months
Allergic Conjunctivitis
Primary: Ocular Itching Score at Day 1 — 0.500; 0.319; 1.867 Score on a scale
Peripheral Artery Disease
Primary: Incidence of Major Adverse Events (MAEs) — 0; 0 participants
Leukemia
Primary: Overall Response (CR for ALL Patients), (CR + CRp for AML Patients) — 1; 2; 0; 2 participants
Heart Failure, Congestive
Primary: Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP or Pulmonary Arterial Diastolic Pressure[PADP]) at 3 Hours — 27.7; 24.8; 29.7; -6.7 Millimeters of…
Eosinophilic Esophagitis
Primary: Percentage of Participants Who Attained Remission. — 65.2; 0 percentage of participants
Rheumatoid Arthritis
Primary: Change From Baseline in Swollen Joint Count — -7.20; -8.68 score on a scale — p=0.278
Risk for Colorectal Cancer
Primary: Number of Participants With Anti Muc-1 Antibody — 39 participants
Fatty Liver
Primary: Normalization or >50% of Serum ALT Levels From Baseline — 7 participants
Major Depressive Disorder (MDD) · Treatment Resistant Depression (TRD)
Primary: MADRS — 14.77; 22.72 units on a scale